SwissBioSim

SwissBioSim is a Swiss biotechnology company specializing in model-informed drug development (MIDD) and in silico clinical trials. The company leverages advanced mathematical modeling and Quantitative Systems Pharmacology (QSP) to simulate drug interactions and predict clinical outcomes in virtual patient populations. By integrating pharmacokinetic and pharmacodynamic (PK/PD) data, SwissBioSim helps pharmaceutical partners optimize dosing regimens, refine trial designs, and improve patient stratification. Their services are designed to reduce the risks, costs, and timelines associated with traditional clinical development. The company focuses on high-complexity therapeutic areas, including oncology, immunology, and rare diseases.